Cleo Diagnostics Ltd (AU:COV) — Market Cap & Net Worth
Market Cap & Net Worth: Cleo Diagnostics Ltd (COV)
Cleo Diagnostics Ltd (AU:COV) has a market capitalization of $47.45 Million (AU$67.06 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #22147 globally and #795 in its home market, demonstrating a -3.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cleo Diagnostics Ltd's stock price AU$0.49 by its total outstanding shares 136862085 (136.86 Million). Review Cleo Diagnostics Ltd (COV) total liabilities to assess the company's total debt and financial obligations.
Cleo Diagnostics Ltd Market Cap History: 2023 to 2026
Cleo Diagnostics Ltd's market capitalization history from 2023 to 2026. Data shows growth from $16.95 Million to $47.45 Million (34.94% CAGR).
Cleo Diagnostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cleo Diagnostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
49.45x
Cleo Diagnostics Ltd's market cap is 49.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $16.95 Million | $110.08K | -$1.73 Million | 153.95x | N/A |
| 2024 | $34.38 Million | $600.15K | -$3.76 Million | 57.28x | N/A |
| 2025 | $58.59 Million | $1.18 Million | -$4.00 Million | 49.45x | N/A |
Competitor Companies of COV by Market Capitalization
Companies near Cleo Diagnostics Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to Cleo Diagnostics Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #147 globally with a market cap of $153.73 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #207 globally with a market cap of $117.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #234 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #247 globally with a market cap of $101.86 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #147 | Abbott Laboratories | NYSE:ABT | $153.73 Billion | $88.41 |
| #207 | Stryker Corporation | NYSE:SYK | $117.79 Billion | $307.80 |
| #234 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #247 | Medtronic PLC | NYSE:MDT | $101.86 Billion | $79.34 |
Cleo Diagnostics Ltd Historical Marketcap From 2023 to 2026
Between 2023 and today, Cleo Diagnostics Ltd's market cap moved from $16.95 Million to $ 47.45 Million, with a yearly change of 34.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$47.45 Million | -19.01% |
| 2025 | AU$58.59 Million | +70.42% |
| 2024 | AU$34.38 Million | +102.86% |
| 2023 | AU$16.95 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Cleo Diagnostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.45 Million USD |
| MoneyControl | $47.45 Million USD |
| MarketWatch | $47.45 Million USD |
| marketcap.company | $47.45 Million USD |
| Reuters | $47.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing int… Read more